VECIMA-NETWORKS
1.5.2024 13:31:31 CEST | Business Wire | Press release
Vecima Networks Inc. (TSX: VCM) will showcase its open, flexible, and interoperable access and video portfolios, including 10G PON fiber access, the new Entra Virtual Cable Modem Termination system (vCMTS), Remote PHY (R-PHY) and market-share-leading Remote MACPHY (R-MACPHY) solutions, and next-generation video delivery, including MediaScale Open Content Delivery Network (CDN)™, and Dynamic Content & Ad Insertion.
Technologies to be on display
The recently announced Entra® vCMTS, part of Vecima’s Entra Cloud™ platform of open, interoperable, cloud-native applications, is built from the ground up to provide the scalability and throughput required for DOCSIS® 4.0 services. It features an open, cloud-native design that is fully containerized and dynamically scalable for operators of every size at market-leading densities.
Built on field-proven Vecima DOCSIS® technology, it is designed to maximize performance while minimizing space, power, and cost. It is interoperable with Vecima’s widely deployed R-PHY Devices (RPDs) and Vecima is fully committed to interoperability with other vendors.
The Entra® SC-1D Entra Access Node offers R-MACPHY in a compact, European form factor. Part of Vecima’s Distributed Access Architecture (DAA) solution that’s deployed in Europe, the SC-1D enables operators to deploy gigabit broadband and new services to residential subscribers and businesses. In addition, moving to DAA delivers sustainability through digitization, enabling substantial energy savings. Dell’Oro Group recently named Vecima as the global revenue share leader in R-MACPHY devices.
The Entra® EN2112 R-PHY Access Node is a high-density, compact, two-port node that’s interoperable with third-party converged cable access platform (CCAP) cores and vCMTS, creating an open, flexible DAA ecosystem. Supporting architectures that push fiber deeper into the network, the EN2112 allows operators to optimize existing hybrid fiber coax (HFC) network capacity and deliver increased bandwidth to subscribers.
Named by Dell’Oro Group as the global market share leader for Remote Optical Line Terminals (R-OLTs) for the third year, Vecima expands its fiber access portfolio with a flexible, compact, and powerful shelf-based platform that supports all predominantly deployed Passive Optical Network (PON) variants. The Entra® EXS1610 All-PON™ Shelf allows customers to selectively deploy fiber to the home in any market hub or outside plant cabinet deployment, allowing maximum flexibility to deploy fiber access solutions based on specific subscriber need. In addition, the EXS1610 interoperates seamlessly with 10 different optical network unit (ONU) vendors, enabling operators to independently select the ONU vendor of their choice.
We will also show MediaScale™ Content Distribution solutions, including Open CDN for high-quality, congestion-free streaming that’s more cost-effective and efficient, and Dynamic Content with Ad Insertion for highly targeted ads and more value per impression.
With MediaScale Open CDN, content owners cut congestion, public CDN costs, and latency, and service providers can monetize the content they’re already delivering. Open CDN delivers video streaming at the highest available bitrates, with zero rebuffering and at an energy-efficient 235 Mbps per watt, while providing the lowest cost of ownership available.
Service providers can gain control over content with the MediaScale Dynamic Content & Ad Insertion solution which supports content rights, blackouts, and advertising. By manipulating content at the edge of the network, operators can deliver more efficient, personalized video content and more opportunities to monetize that content with targeted, higher-value ads.
Vecima speakers at ANGA COM
Vecima’s Chris Busch, Principal Access Architect Office of CTO, will speak on “Low Latency in Fiber and HFC Networks” on Tuesday, May 14.
Quotes from Vecima executives attending ANGA COM
“Vecima continues to expand its European footprint, bringing proven, market-leading solutions for access and IP video to our customers,” said John Ruwe, Vice President of EMEA Sales at Vecima. “With our valued partners in the region, we’re helping operators build the fiber, cable, and video networks that open up new services for their subscribers.”
“We meet operators where they are, offering multiple options to evolve their networks to meet the broadband demands of the future,” said Ryan Nicometo, Senior Vice President and General Manager, Video & Broadband Solutions at Vecima. “At Vecima, we take an open, interoperable approach that gives operators ultimate flexibility to choose the path that takes them to the future.”
Visit Vecima Networks at ANGA COM 2024
May 14-16 Cologne, Germany
Koelnmesse Hall 8, Stand A20
To schedule a meeting with the Vecima team, contact us at sales@vecima.com.
Media and industry analysts, please contact bernadette.dunn@vecima.com.
About Vecima Networks
Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multigigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive.
Learn more at vecima.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240501888729/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom